BeiGene (BSP:B1GN34) 3-Year Revenue Growth Rate : 85.30% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BeiGene 3-Year Revenue Growth Rate?

BeiGene's Revenue per Share for the three months ended in Dec. 2023 was R$2.30.

During the past 12 months, BeiGene's average Revenue per Share Growth Rate was 71.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 85.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 43.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 73.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of BeiGene was 494.10% per year. The lowest was -45.70% per year. And the median was 68.90% per year.

Competitive Comparison of BeiGene's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, BeiGene's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BeiGene's 3-Year Revenue Growth Rate falls into.

BeiGene 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

BeiGene (BSP:B1GN34) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

BeiGene 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BeiGene's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BSP:B1GN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines